Alendronate has a residual effect on bone mass in postmenopausal Danish women up to 7 years after treatment withdrawal

Bone

Volumn 33, Issue 3, 2003, Pages 301-307

  Bagger, Yu Z ^a   Tankó, László B ^a   Alexandersen, Peter ^a   Ravn, Pernille ^a   Christiansen, Claus ^a  

^a CENTER FOR CLINICAL AND BASIC RESEARCH   (Denmark)

Author keywords

Alendronate; Bone mineral density; Bone turnover; Early postmenopausal women; Residual effect

Indexed keywords

ALENDRONIC ACID; BIOCHEMICAL MARKER; COLLAGEN TYPE 1; OSTEOCALCIN;

ADULT; ARTICLE; BONE DENSITY; BONE MASS; CALCIUM HOMEOSTASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENMARK; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOLLOW UP; FOREARM; HIP; HUMAN; INFORMED CONSENT; LUMBAR SPINE; OSTEOLYSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT WITHDRAWAL;

EID: 0041331740     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(03)00112-1     Document Type: Article

References (22)

1. Raisz L.G., Prestwood K.M. Epidemiology and pathogenesis of osteoporosis. Clin Cornerstone. 2:2000;1-10.
2. Fleisch H. Mechanisms of action of the bisphosphonates. Medicina (B Aires). 57:(Suppl 1):1997;65-75.
3. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 348:1996;1535-1541.
4. Ravn P., Bidstrup M., Wasnich R.D., Davis J.W., McClung M.R., Balske A., et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial . Ann Intern Med. 131:1999;935-942.
5. Liberman U.A., Weiss S.R., Broll J., Minne H.W., Quan H., Bell N.H., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 333:1995;1437-1443.
6. Ravn P., Weiss S.R., Rodriguez-Portales J.A., McClung M.R., Wasnich R.D., Gilchrist N.L., et al. Alendronate in early postmenopausal women effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group . J Clin Endocrinol Metab. 85:2000;1492-1497.
7. McClung M., Clemmesen B., Daifotis A., Gilchrist N.L., Eisman J., Weinstein R.S., et al. Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med. 128:1998;253-261.
8. Hosking D., Chilvers C.E., Christiansen C., Ravn P., Wasnich R., Ross P., et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med. 338:1998;485-492.
9. Christgau S., Rosenquist C., Alexandersen P., Bjarnason N.H., Ravn P., Fledelius C., et al. Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. Clin Chem. 44:1998;2290-2300.
10. Rosenquist C., Qvist P., Bjarnason N., Christiansen C. Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies. Clin Chem. 41:1995;1439-1445.
11. Stock J.L., Bell N.H., Chesnut C.H. III, Ensrud K.E., Genant H.K., Harris S.T., et al. Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med. 103:1997;291-297.
12. Tonino R.P., Meunier P.J., Emkey R., Rodriguez-Portales J.A., Menkes C.J., Wasnich R.D., et al. Skeletal benefits of alendronate 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group . J Clin Endocrinol Metab. 85:2000;3109-3115.
13. Heaney R.P., Yates A.J., Santora A.C. Bisphosphonate effects and the bone remodeling transient. J Bone Miner Res. 12:1997;1143-1151.
14. Chavassieux P.M., Arlot M.E., Reda C., Wei L., Yates A.J., Meunier P.J. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest. 100:1997;1475-1480.
15. Parfitt A.M., Mundy G.R., Roodman G.D., Hughes D.E., Boyce B.F. A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J Bone Miner Res. 11:1996;150-159.
16. Orr-Walker B., Wattie D.J., Evans M.C., Reid I.R. Effects of prolonged bisphosphonate therapy and its discontinuation on bone mineral density in post-menopausal osteoporosis. Clin Endocrinol (Oxf). 46:1997;87-92.
17. McClung M., Omizo M., Ravn P., Hosking D., Wu M., Kaur A., et al. Resolution of effect following alendronate six-year results from the Early Postmenopausal Interventional Cohort (EPIC) Study . J Bone Miner Res. 17:(Suppl 1):2002;134.
18. Ravn P., Hosking D., Thompson D., Cizza G., Wasnich R.D., McClung M., et al. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab. 84:1999;2363-2368.
19. Bjarnason N.H., Christiansen C. Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women. Bone. 26:2000;561-569.
20. Gertz B.J., Holland S.D., Kline W.F., Matuszewski B.K., Porras A.G. Clinical pharmacology of alendronate sodium. Osteoporos Int. 3:(Supply 3):1993;S13-S16.
21. Lin J.H. Bisphosphonates a review of their pharmacokinetic properties . Bone. 18:1996;75-85.
22. Fleisch H.A. Bisphosphonates preclinical aspects and use in osteoporosis . Ann Med. 29:1997;55-62.